20 results about "Differentiation Antigens" patented technology

As described below, the present disclosure features polypeptides capable of binding a cluster of differentiation 5 (CD5) antigen and polynucleotides encoding said CD5-binding polypeptides, compositions comprising the same, and methods for use thereof. The disclosure also features lipid nanoparticles comprising the CD5-binding polypeptides and methods for use thereof for delivery of a polynucleotide (e.g., a polynucleotide encoding a chimeric antigen receptor) to a T cell in vivo.

The present disclosure generally relates to binding agents that are capable of targeting tumor cells and immune cells. The binding agents of the present disclosure are multispecific and comprise antigen binding domains that are capable of binding to Dopamine Receptor D2 (DR2), to Programmed Cell Death Protein 1 (PD-1) and / or to Cluster of Differentiation 47 (CD47). The multispecific binding agents of the present disclosure may be used to treat subjects in need thereof.

To provide effective bispecific antibodies for use in cancer treatment.SOLUTION: Provided is a polypeptide comprising an antigen binding fragment, wherein the antigen binding fragment comprises CDR-L, CDR-H, FR-L, and FR-H, wherein the antigen binding fragment specifically binds to cluster of differentiation 3 (CD3) T cell receptor; comprises a variable heavy chain (VH) amino acid sequence having at least 90% identity to an amino acid sequence having a specific sequence; and comprises at least 99% identity or at least 90% identity to a variable light chain (VL) amino acid sequence having a specific sequence.SELECTED DRAWING: Figure 4

The present invention belongs to the field of immune cell therapy technology, and specifically relates to a chimeric signal receptor for targeting leukocyte differentiation antigen 56 (CD56) and a cell for expressing the receptor. The structure of the chimeric signal receptor comprises a signal peptide, an extracellular antigen recognition region, an extracellular hinge region, a transmembrane region and an intracellular signal region; the chimeric signal receptor can specifically recognize the CD56 protein expressed by normal cells or tumor cells, and convert it into an activation signal inside the immune cells, participate in the proliferation and survival of immune cells, and enhance the activity of immune cells. The present invention also provides cells expressing the chimeric signal receptor. The cells of the present invention can be used as cell therapy drugs, and have good application prospects in the treatment of diseases such as tumors and autoimmune diseases.

The invention belongs to the technical field of biomedical detection, and discloses a blood cell analysis system based on image flow cytometry, which comprises a cell staining module, the dyeing module simultaneously comprises a first fluorescent probe capable of being specifically combined with components in a cell nucleus or enriched in the cell nucleus, a second fluorescent probe capable of being specifically combined with cell nucleus DNA and a third fluorescent probe capable of being specifically combined with a blood cell differentiation antigen; an image flow cytometer; and the image processing module is used for calculating the kernel detection rate and / or the average kernel number. According to the present invention, the combination of the specific types of the cell staining dyes is adopted, the image flow cytometry is matched, and the optimized multi-dimensional fluorescence staining combination and the matched automatic image analysis process are adopted to achieve the synchronous, high-throughput and accurate quantitative analysis of the blood cell immune phenotype and the cell morphology key characteristics at the single cell level;

The presently disclosed subject matter provides methods and compositions for treating cancer (e.g., melanoma). It relates to chimeric antigen receptors (CARs) that specifically target MDA (e.g., Trp1), and immunoresponsive cells comprising such CARs. The presently disclosed MDA-specific CARs have enhanced immune-activating properties, including anti-tumor activity.

This invention discloses a quality control sample for flow cytometry detection of leukocyte differentiation antigen CD34 and its preparation method, relating to the field of flow cytometry quality control technology. The preparation method of this invention successfully prepared a quality control sample for flow cytometry detection of leukocyte differentiation antigen CD34. The quality control sample for flow cytometry detection of leukocyte differentiation antigen CD34 provided by this invention, as the first domestic quality control sample for CD34 flow cytometry counting, fills a gap in this product field in China. This quality control sample has performance close to imported reagents, uses the same operating method, and does not incur additional learning costs; furthermore, the product's shelf life can be stably maintained at 45–50 days, and its usage cost is far lower than imported quality control samples.

The present invention provides a method of dosing an anti-fragment crystallizable receptor-like 5 (FcRH5) / anti-cluster of differentiation 3 (CD3) bispecific antibody and lenalidomide for the treatment of cancers such as multiple myeloma.

The invention relates to the technical field of immunoglobulins, in particular to an anti-human myeloid cell nucleus differentiation antigen (MNDA) monoclonal antibody and a hybridoma cell strain and application thereof. The invention provides an anti-human myeloid cell nucleus differentiation antigen (MNDA) monoclonal antibody, and also provides a hybridoma cell strain OTI4H6, the hybridoma cell strain OTI4H6 is preserved in the China General Microbiological Culture Collection Center (CGMCC) on November 28, 2024, and the preservation number of the hybridoma cell strain OTI4H6 is No.46245. The invention further provides an anti-human myeloid cell nucleus differentiation antigen (MNDA) monoclonal antibody. The hybridoma cell strain OTI4H6 provided by the invention can stably secrete an anti-human myeloid cell nucleus differentiation antigen (MNDA) monoclonal antibody, and can be specifically combined with MNDA protein, so that the specificity, accuracy and reliability of immunodetection are remarkably improved, and the hybridoma cell strain OTI4H6 can be suitable for marking the MNDA protein in tissue cells.

This specification provides, in particular, an antibody-binding domain for the differentiation antigen group 3 T cell receptor (CD3), an antibody-binding domain for the epidermal growth factor receptor (EGFR), a cleavable linker sequence, and a protease-activatable bispecific fusion protein, such as a protease-activatable T cell engager, as well as therapeutic uses and methods.

The invention relates to a method for measuring a female aging marker and a female aging clock, and belongs to the technical field of medical examination. A group of female senescence markers comprises a plurality of cell factors related to female senescence, and the cell factors comprise but are not limited to a cell factor 6Ckine, a cancer antigen 125, a leukocyte differentiation antigen 14, a leukocyte differentiation antigen 99-L2, follicle stimulating hormone, a growth differentiation factor 15, a low-density lipoprotein receptor, a neutrophil activating protein-2, and a cell factor Ckine. P-hydroxybenzoate esterase and a vascular endothelial growth factor C. The method has the advantages that a group of specific senescence markers related to female senescence are confirmed, a female biological senescence clock determination model is constructed, and the biological age of a female individual is evaluated and the senescence speed is predicted through quantitative analysis of the biomarkers.

The invention discloses a quality control product for flow detection of a leukocyte differentiation antigen CD34 and a preparation method, and relates to the technical field of quality control products for medical detection. According to the preparation method of the quality control product for flow cytometry of the leukocyte differentiation antigen CD34, provided by the invention, by adopting the microsphere coupled CD34 and CD45 proteins to replace genetically engineered cells and utilizing the physical stability and uniform particle size distribution of a microsphere material, the batch consistency of the quality control product is remarkably improved, and meanwhile, the efficacy period of the product is prolonged. Furthermore, in a peripheral blood treatment link, through sequence optimization of firstly fixing peripheral blood cells, then adding back plasma and finally mixing with the microspheres, stabilization of a cell membrane structure is facilitated, and release of endogenous interfering substances due to cell rupture is effectively avoided. The optimization of the sequence enables the quality control product to be closer to the real processing condition of a clinical sample, so that the specificity and the signal-to-noise ratio of a flow detection signal are improved, and the correlation between a quality control result and clinical actual detection is enhanced.

Provided is a method for treating liver cancer. The method includes administrating a therapeutic effective amount of a memory lymphocyte population to a subject in need thereof. The memory lymphocyte population contains at least one of the following marker molecules: leukocyte differentiation antigens CD3, CD4, CD8, CD16, CD56, CD62L and CD45RO.

The invention discloses a specific antibody for resisting Crassostrea gigas granulocyte membrane surface differentiation antigen protein CD22, the specific antibody is obtained by immunizing Balb / c mice by using recombinant protein of the Crassostrea gigas granulocyte membrane surface differentiation antigen protein CD22, and the recombinant protein completely contains all extracellular Ig, IGc2 and Ig-like functional domains of the Crassostrea gigas granulocyte membrane surface differentiation antigen protein CD22. The specific antibody can specifically recognize a CD22 recombinant protein with the molecular weight of 61.3 kDa and a blood lymphocyte natural protein with the molecular weight of 102.8 kDa, and it is detected that the CD22 protein is mainly expressed on cell membranes of part of agranulocytes. The specific antibody provided by the invention can be used for identifying and sorting the Crassostrea gigas CD22 + agranulocyte, and provides an important tool for deeply researching the phenotype and function of the CD22 + agranulocyte and the effect of the CD22 + agranulocyte in immune response.

This specification provides human differentiation antigen group 6 (CD6) binding molecules and nucleic acid sequences encoding such molecules. In certain embodiments, this specification provides a first single-monomer variable antibody domain (SMVAD) comprising a specific CDR and, optionally, a human CD6 binding molecule (e.g., a nanobody) having a second single-monomer variable antibody domain, and a method for treating T-cell-related diseases (e.g., cancer, e.g., T-cell lymphoma) using such molecules. In certain embodiments, the SMVAD comprises a camelid, human, or humanized framework region.

This specification provides, in particular, an antibody-binding domain for the differentiation antigen group 3 T cell receptor (CD3), an antibody-binding domain for the epidermal growth factor receptor (EGFR), a cleavable linker sequence, and a protease-activatable bispecific fusion protein, such as a protease-activatable T cell engager, as well as therapeutic uses and methods.

The present application relates to the field of vaccines, in particular to an engineered myeloid cell and a preparation method and use thereof. The present application provides an antigen-modified gel, an engineered myeloid cell and use thereof, wherein the antigen-modified gel comprises a plurality of immunostimulants and tumor antigens, attracts monocytes to migrate into and differentiate into antigen-presenting cells, and the activated and antigen-loaded monocytes further migrate out of the gel to lymph nodes, and can efficiently induce an anti-tumor immune response of lymphocytes such as T cells.

This application relates to the technical field of immunoglobulins, specifically to anti-human myeloid nuclear differentiation antigen (MNDA) monoclonal antibodies, their hybridoma cell lines, and applications. This application provides an anti-human myeloid nuclear differentiation antigen (MNDA) monoclonal antibody. At the same time, this application also provides the hybridoma cell line OTI4H6, which was deposited on November 28, 2024, at the China General Microbiological Culture Collection Center (CGMCC), and its deposit number is No. 46245. The hybridoma cell line OTI4H6 provided by this application can stably secrete an anti-human myeloid nuclear differentiation antigen (MNDA) monoclonal antibody, and can specifically bind to the MNDA protein, significantly improving the specificity, accuracy, and reliability of its immunoassay, and is applicable to the labeling of MNDA protein in tissue cells.

The utility model discloses a leukocyte differentiation antigen kit, which relates to the technical field of antigen kits and comprises a kit body, a frame is slidably arranged in the kit body, a transverse plate is fixedly connected in the frame, through holes are formed in the upper surfaces of the transverse plate and the frame, and the transverse plate is fixedly connected with the frame through the through holes. Test tubes are inserted into the two corresponding through holes, a pop-up mechanism is arranged between the frame and the lower surface of the interior of the kit body, a kit cover is arranged above the kit body, fixing mechanisms are arranged on the two sides of the kit body, the kit cover is fixedly connected to the upper portion of the kit body through the fixing mechanisms, and the kit cover is fixedly connected to the upper portion of the kit body through the fixing mechanisms. And a pressing mechanism is arranged on the lower surface in the box cover. The push plate can be driven by resilience force of each first spring to move upwards and push out the frame, so that each test tube can be taken out together, and each damper can be used for preventing the test tubes from popping up due to too fast resilience of the first springs in the process.

The present invention discloses a quality control product and a preparation method for flow cytometry detection of leukocyte differentiation antigen CD34, and relates to the technical field of quality control products for medical detection. The preparation method of the quality control product for flow cytometry detection of leukocyte differentiation antigen CD34 provided by the present invention, by adopting microspheres coupled with CD34 and CD45 proteins to replace genetically engineered cells, and utilizing the physical stability and uniform particle size distribution of the microsphere material, significantly improves the consistency of quality control products between batches, while extending the shelf life of the product. Furthermore, in the peripheral blood processing link, by optimizing the sequence of first fixing the peripheral blood cells, then adding back the plasma, and finally mixing with the microspheres, it helps to stabilize the cell membrane structure and effectively avoids cell rupture and the release of endogenous interfering substances. The optimization of this sequence makes the quality control product closer to the actual processing conditions of clinical samples, which not only improves the specificity and signal-to-noise ratio of the flow detection signal, but also enhances the correlation between the quality control results and actual clinical detection.